A Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

Trial Profile

A Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs DHACM (Primary)
  • Indications Pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MiMedx
  • Most Recent Events

    • 17 Jan 2018 According to a MiMedx media release, the first patients have been enrolled and randomized in in the Orthopedic/Sports Medicine area.
    • 17 Jan 2018 Status changed from planning to recruiting, as reported in a MiMedx media release.
    • 07 Sep 2017 According to a MiMedx media release, the Company has been notified by the Food and Drug Administration (FDA) that the Investigational New Drug (IND) Phase 3 Achilles Tendonitis clinical study may proceed. The Company expects patient enrollment to commence in the next quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top